Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | D101Y |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR2 D101Y lies within the extracellular Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). D101Y results in a growth advantage relative to wild-type Fgfr2 in a competition assay (PMID: 34272467) and increased transformation activity in cultured cells (PMID: 34272467, PMID: 18552176). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 D101Y |
Transcript | NM_000141.5 |
gDNA | chr10:g.121565513C>A |
cDNA | c.301G>T |
Protein | p.D101Y |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001144913 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_000141 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001144914 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001320658 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001144917.1 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_022970 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001320658.1 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001144917.2 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001320658.2 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001144917 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121565513C>A | c.301G>T | p.D101Y | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 D101Y | Advanced Solid Tumor | predicted - sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 D101Y | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 D101Y | Advanced Solid Tumor | predicted - resistant | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 D101Y were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
FGFR2 D101Y | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 D101Y | Advanced Solid Tumor | predicted - sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 D101Y | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 D101Y | Advanced Solid Tumor | predicted - sensitive | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 D101Y were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |